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Aim: An estimated 1.1% of Australian adults are infected with hepatitis C virus (HCV). Many develop chronic liver disease, and some develop
liver failure or hepatocellular carcinoma. HCV infection in Australian children is poorly deﬁned. We aimed to determine the reported incidence,
clinical and epidemiological features of newly diagnosed HCV infection in Australian children presenting to paediatricians.
Methods: We undertook prospective active national surveillance, using the Australian Paediatric Surveillance Unit, of incident HCV cases in
children aged <15 years between 1st January 2003, and 31st December 2007.
Results: There were 45 conﬁrmed cases of newly diagnosed HCV infection over ﬁve years (<1 per 100 000 children aged <15 years per year).
Median age at diagnosis was 2.9 years. Positive maternal HCV serostatus was themost frequent reported risk factor for HCV infection in children
(40/45). Three children (all aged > 14), were exposed through their own IV drug use. No children were co-infected with HIV and only one child was
co-infected with HBV. All children were asymptomatic at diagnosis, although many had minor elevations in liver transaminases. Many clinicians
reported difﬁculties with follow-up.
Conclusions: Childhood HCV infection is uncommon in Australia, although our data likely underestimate the incidence. Only a small number
of children aged <18 months was identiﬁed, despite known perinatal exposure. Opportunistic investigation of children at risk for HCV, improved
education regarding vertical transmission for health care providers, and increased coordination of childhood HCV services are required to
improve recognition and management of children with HCV.
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What is already known on this topic
1 Childhood HCV is most commonly acquired through vertical
transmission.
2 Australian data on childhood HCV is poorly deﬁned.
3 New antiviral therapies are better tolerated and show greater
efﬁcacy for HCV clearance.
What this paper adds
1 Childhood HCV infection in Australia is uncommon and likely
unrecognised due to missed opportunities for screening of HCV
exposed infants.
2 Maternal HCV seropositivity was the most common risk factor
for childhood infection.
3 High risk behaviour (tattoos, and IV drug) in children is another
important source of HCV infection.
The global prevalence of hepatitis C Virus (HCV) infection is
estimated to be 3% with approximately 3–4 million new infec-
tions each year.1 In Australia approximately 1% of the adult
population are infected.2 Infection is via blood to blood contact,
and since the introduction of blood donor screening in Australia
between 1989–1990 the most common infection route in adults
is through sharing needles and injecting paraphernalia.3 Infec-
tion in children is typically through perinatal transmission by
women who are HCV RNA positive at delivery. The overall risk
of vertical transmission is approximately 5% although this
varies according to maternal risk factors, such as maternal
co-infection with human immunodeficiency virus (HIV),4,5
maternal history of injecting drug use4,6,7 and prolonged rupture
of membranes.8 The evidence regarding high maternal HCV
viral load and mode of delivery is conflicting and inconclusive.7,8
Similarly there remain many gaps in our understanding of
childhood HCV infection.
The natural history of HCV infection in children is not fully
described. Chronically infected children are usually asympto-
matic, having normal to mildly elevated transaminases
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irrespective of the mode of HCV acquisition.9,10 HCV persistence
has been reported in between 80–90% of children.9,11 Sponta-
neous clearance of HCV is reported in up to 27% of perinatally
infected infants, usually occurs by school age, and is highest in
children infected with HCV genotype 3.12 Histological assessment
of liver biopsies suggests that inflammatory activity is usually
mild in children with chronic HCV infection.13,14 There are
however, reported cases of bridging fibrosis, cirrhosis and hepa-
tocellular carcinoma in the literature.14–16 Although liver fibrosis
in children can be stabilised or reversed with pegylated interferon
and ribavirin antiviral therapy,17,18 the best method for reducing
the risk of disease progression from HCV is early identification
and initiation of antiviral treatment. In Australia, treatment has
been limited by incomplete identification of cases and, in the
past, availability of therapy.19 In the current era of oral
pangenotypic treatment for HCV, with rates of cure greater than
90%, it is even more important to identify children at risk early
and treat them if they do not clear the virus spontaneously.20
The incidence and risk factors for childhood HCV infection in
Australia are poorly defined. Australian studies of paediatric
HCV infection report a bleak picture including: variable antena-
tal screening in high-risk groups,21 lack of parental understand-
ing of HCV transmission and a reluctance to screen children,22
and poor coordination and follow up of HCV infected children
in some centres.21 Increasing our understanding of risk factors
and presentation in childhood HCV is important to improve
outcomes and service delivery to infected children. Therefore
the aim of our study was to use national active surveillance to
determine the incidence of newly diagnosed HCV infection in
children presenting to Australian paediatricians and to describe
the risk factors, clinical presentation, investigation, manage-
ment, and co-infection with hepatitis B virus (HBV) and human
immunodeficiency (HIV) in these children.
Methods
Children were identified through the Australian Paediatric
Surveillance System (APSU)23 from 1st January 2003, to 31st
December 2007. The APSU conducts active national surveil-
lance of rare childhood conditions, through monthly reporting
by paediatricians (>1300).
Eligible children were aged <15 years with a newly diagnosed
HCV infection. A confirmed case of HCV infection was defined
as: 1) at least one confirmed positive anti-HCV antibody test
performed ≥ 18 months of age, or 2) a positive anti-HCV anti-
body test on a single occasion and a positive test for HCV RNA
(PCR or RT-PCR) on a single occasion at any age >1 month of
age, 3) or a positive HCV RNA test (PCR or RT-PCR) on two
separate occasions.
Once an eligible child with a newly diagnosed HCV infection
was notified, the reporting paediatrician completed a study
questionnaire. Data collected included the child’s age, country
of birth, date of diagnosis, sex, maternal country of birth,
known child and maternal risk factors for HCV (e.g. perinatal,
recipient of blood/blood product exposure or organ transplant,
and lifestyle exposures), co-infections (human immunodefi-
ciency virus (HIV), hepatitis B (HBV)), maternal HCV history,
clinical symptoms, diagnosis, liver function test results, and
treatment.
Ethical approval for this study was obtained from University
of New South Wales (HREC-02376). The protocol and question-
naire are available from www.apsu.org.au.
Statistical analysis
Comparisons of categorical data were undertaken using χ2 test
or Fisher’s exact test for small cells, or one sample binomial
t-test, where appropriate.
To estimate the minimum population incidence of HCV for
children aged between 0 and 15 years, we used the 30 June
2001 age standardised data cube as recommended by Austral-
ian Bureau of Statistics and Australian Institute of Health and
Welfare.24 We summed the data for the population age catego-
ries to get a total population and then calculated the incidence
rate per 100 000 with 95% confidence intervals (CI) as per
standard calculations. Age is presented as decimal age. We
compared proportions of maternal country of birth, and mode
of birth to those reported in Australia’s Mothers and Babies to
the mid-year of the data collection period (2005) using
z-tests.25 We tabulated our incident cases by year and age cat-
egories with HCV cases (both ‘newly acquired’ and ‘unspeci-
fied’) reported to the National Notifiable Disease Surveillance
System (NNDSS).26
Presentation of cells with small numbers and identifiable
characteristics have been limited.27 Statistical analysis was done
using SPSS version 22.0 (SPSS Inc. Released 2013. PASW Sta-
tistics for Windows, Version 22.0, Chicago: SPSS Inc.).
Results
There were 92 notifications over the five year study period, and
detailed questionnaires were provided for 80 (87% response), of
which 45 were confirmed cases of childhood HCV infection. The
remaining notifications were either reporting errors (n = 26), or
duplicate notifications (n = 9). Of the reporting errors, age was
a common error with 7 children aged ≥15 years. Notifications
were evenly distributed over the study period (P = 0.50). The
reported incidence was 0.21 (95% CI 0.15 to 0.27) per 100 000
children <15 years. There were approximately six fold (n = 265)
more HCV notifications reported to the NNDSS for the same age
range and time period (Table 1).
Demographic and birth characteristics of HCV
infected children
The median age at diagnosis of HCV infected children was 2.95
years (range 1.1 months to 14.87 years) (Fig. 1). There were no
sex differences (χ2 = 0.22, df = 1, P = 0.64), and the majority of
children was Australian born (Table 1). Indigenous status was
not reported. Most children were born by normal vaginal deliv-
ery, and route of delivery was not statistically different from
national reported birth data (29.4% vs. 22%, z-test 1.9, P =
0.64). Mothers of HCV infected children were predominantly
Australian born (72%), and the proportion was not statistically
different to Australian birth record data (76.8%, z-test 1.6, P =
0.10). There was no identified pattern to the country /region of
maternal origin (e.g. Asia or European) (Table 2).
C Raynes-Greenow et al.Incident childhood HCV in Australia
Journal of Paediatrics and Child Health 51 (2015) 1115–1120
© 2015 The Authors
Journal of Paediatrics and Child Health © 2015 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
1116
Indications for HCV investigation, child and
maternal HCV risk factors and diagnostic tests
Information on the ‘reason for investigation’ of the child was
reported for 38/45 cases. The most frequent reason stated for
HCV investigation was known maternal HCV infection. For six
children (aged 1.4 to 11.6 years), investigation for HCV was
prompted by identification of abnormal liver function during
investigations for another illness (Table 3).
HCV risk factors were reported for all children. The most
frequent risk factor was maternal HCV infection but three chil-
dren (all aged >14 years), were exposed through their own IV
drug use. Other risk factors included receipt of immunisation or
injections in countries outside Australia (Table 3).
Maternal risk factors were well reported (Table 3). The major-
ity of mothers of HCV infected children were reported to have a
history of IV drug use. One mother reported blood/blood
product exposure, three women reported possible exposure
through other health care (e.g. childhood surgery). Other risk
factors included other drug use,3 tattooing and/or body pierc-
ing,9 or needlestick injury.2 No mothers were reported to be
health care workers and or to have been incarcerated. Ten
women reported multiple risk factors for HCV including com-
binations of IV drug use and tattoo/body piercing, blood/blood
product and other needlestick injury (Table 3). Only one of the
overseas born mothers was reported to be an IV drug user.
Maternal HCV and other blood borne virus results
Positive maternal HCV serostatus was reported for 40 children.
Of the four mothers with a known date of HCV diagnosis, two
Table 1 Notiﬁcation of childhood cases of HCV by year and age on the NNDSS† and the APSU‡, 2003–2007
2003 2004 2005 2006 2007
Age NNDSS APSU NNDSS APSU NNDSS APSU NNDSS APSU NNDSS APSU
0–4 26 5 40 8 19 5 22 4 24 2
5–9 6 3 10 1 10 1 9 0 10 4
10–14 12 3 10 3 12 2 62 4 22 0
Total 44 11 60 12 41 8 93 8 56 6
†NNDSS, National Notiﬁable Disease Surveillance System, newly acquired cases, and unspeciﬁed cases combined.26
‡APSU, Australian Paediatric Surveillance Unit, incident cases.
Fig. 1 Age distribution of incident cases of
HCV in childhood (<15 years) reported to the
APSU, 2003–2008 Australia.
Table 2 Demographic and birth characteristics of HCV infected chil-
dren aged <15 years in Australia, 2003–2007
Variable N = 45
Sex
Male 19
Female 22
Not reported 4
Median age at notiﬁcation (years) (min, max) 3.0 (1.1 months, 14.9 yrs)
Child country of birth
Australia 39
Other† 5
Not reported 1
Maternal country of birth
Australia 32
Other‡ 6
Not reported 7
Mode of Birth
Vaginal 20
Assisted vaginal 2
Caesarean section 10
Not reported 13
Breast feeding
Any 14
Not reported 31
†France, Japan, Kyrgyzstan, Pakistan, USSR.
‡France, Japan, Kyrgyzstan, New Zealand, Pakistan, USSR, Vietnam.
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were diagnosed during antenatal care. Maternal HCV RNA
results were reported for 23/46, of which 20 were positive.
Results of maternal testing for these other blood borne viruses
were not available in all women. Of those tested, two HCV
infected mothers were co-infected with HIV alone, and two
others with HBV alone (Table 3).
Clinical features and laboratory testing
Almost all children were asymptomatic (40/45) at the time of
HCV diagnosis with no reports of jaundice, or signs of liver
failure. Two children had hepatomegaly, and one had bruising.
Eight children were aged <18 months at the time of their HCV
diagnosis. All were HCV antibody positive and RNA positive.
Almost all children were tested for HCV antibody (41/45), and
all tested were seropositive. A repeat HCV antibody test was
reported for 21 children (aged 1 month to 15 years) of whom 18
were positive, one child aged <18 months was indeterminate on
repeat test but the RNA test was positive.
Of the 41 seropositive children, 39 were tested and positive
for HCV RNA. Of these, genotype was reported for nine chil-
dren, six children were infected with HCV genotype 1 (1 = 1, 3
= 1a, 1 = 1b, 1 = 1a/b), one with genotype 2, and another two
with genotype 3a.
Liver function tests were reported for 46/48 children. LFT
abnormalities at any time were reported for 29/46; the highest
reported ALT was 379 and the highest AST level was 232. Two
children had liver biopsies both of which were abnormal: one
showed mild fibrosis and moderate inflammation and the other
mild steatosis, minimal necroinflammatory activity, and no
fibrosis. No children were reported to be co-infected with HIV,
although the status of 13 was ‘unknown’. Only one child was
reported to be co-infected with HBV, the status of another nine
was ‘unknown’.
Therapy
Information on therapy for HCV was available for 41/45: no
child had been treated with antiviral therapy at the time of the
notification. Open field comments regarding ongoing clinical
care suggested that there was frequent non-attendance at clinic
appointments despite attempts by clinic staff to engage families.
Discussion
This five year national surveillance for newly diagnosed child-
hood cases of HCV suggests a minimum incidence of <1 per
100 000 children aged <15 years in Australia. The median age at
diagnosis was just before the third birthday, only a small
number of children being identified under 18 months). This is
despite the fact that most of these children are from high risk
groups with mothers who were HCV positive and using IV
drugs.
We identified 45 newly diagnosed cases of childhood HCV
infection over the study period through the APSU mechanism
and obtained detailed epidemiological data not available
through passive reporting systems. Our data are likely to be an
under-estimate of the true incidence. Comparison with passive
laboratory notifications of newly acquired and unspecified HCV
infections made through the NNDSS showed that there were
approximately six-fold more cases identified through the latter
system for the same time period. The reasons for the difference
are likely to be differences between the two mechanisms: the
APSU relies on active reporting of HCV cases referred to spe-
cialist paediatricians in response to a monthly prompt, but this
relies upon voluntary reporting and paediatricians are unlikely
to see all cases. The NNDSS mechanism is mandatory through
pathology providers, so ascertainment may be higher but it does
not obtain detailed epidemiological and clinical information.
Similarly, a discrepancy was noted when incident cases referred
to a liver clinic at a NSW children’s hospital were compared with
state-based public health notifications for the same period.28
These examples provide evidence of the gap between identifi-
cation of HCV infection in children and referral to specialty child
services.
HCV incidence estimates obtained through modelling29
suggest that there are between 125 − 250 children born each
year in Australia who are infected with HCV.30 This suggests that
mandatory laboratory notification systems also underestimate
disease burden. Reasons for this include under detection of HCV
infected mothers during the antenatal period and therefore sub-
optimal HCV screening of all HCV exposed infants and children.
Antenatal screening practices varied in widely Australia during
the period of surveillance.21,31 The most recent statement from
the Royal Australian and New Zealand College of Obstetricians
and Gynaecologists recommends all pregnant women should be
screened for antibody to HCV32 and differs to the current Aus-
tralian national HCV testing policy.33 Antenatal screening does
Table 3 Indication for HCV testing, child and maternal HCV risk factors
Variable N = 45
Reason for testing child for HCV
Known maternal HCV infection 29
Other carer infected 2
Routine investigation for other illness 6
Not stated 8
Known child HCV risk factors†
Mother HCV positive 39
Infected family member 13
Child transfusion recipient 2
Child IV drug 2
Other immunisation/IM injections 2
Known maternal HCV risk factors†
IV Drug use 31
Tattoo/body piercing 9
Other health care 3
Other drug use 3
Needlestick injury 2
Blood/blood product recipient 1
Not known/not reported 9
Maternal co-infection
HIV (n = 31 tested) 2
HBV (n = 26 tested) 2
†Multiple risk factors.
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not confer benefit on vertical transmission rates but does
improve outcomes for infected children.28,31,34 Previous Austral-
ian data highlighted that knowledge of HCV vertical transmis-
sion and uptake of screening remains low in high risk
populations, and suggests that novel educational strategies are
needed to improve health outcomes in HCV exposed infants and
children.22,31 The antenatal period is an excellent opportunity
for HCV screening, with 99.9% of women in Australia having at
least one antenatal visit, and almost 95% having greater than
five.35 Data on screening for HCV infected mothers and children
for HIV and HBV co-infection in our study were often not
available and suggest that there may be missed opportunities for
screening of other blood-borne viruses too. Antenatal screening
will provide opportunities for improved care of HCV infected
women and their infected offspring, including specialist paedi-
atric care and vaccination for hepatitis A (after 2 years of age).30
However, even if a women is identified as HCV seropositive
through antenatal screening, previous research suggests less
than 20% of infected mothers have their children tested for
HCV as they assume the children are not HCV positive.22 Failure
to test means children miss early opportunities for diagnosis and
monitoring and mothers and carers miss opportunities for edu-
cation and counselling and there is a future risk of infection for
subsequent pregnancies.22 Further, there are considerable public
health costs of under-ascertainment. A US study in 2011 esti-
mated that chronic HCV infection costs approximately
US$65 000 per person, and these costs are significantly
increased in children with a longer period of disease infection.36
Early detection and improved ascertainment will both improve
clinical outcomes but also reduce health costs.
Injecting drug use was the most frequent maternal risk factor
for HCV infection, and in older children was also an identified
risk factor for infection. This knowledge offers an important
target group for prevention. Globally, the HCV disease burden
due to injecting drug use has recently been estimated to account
for over 500 000 DALYs (disease adjusted life years).37
Data on long term outcomes were not available from this
study, due to low attendance by families to health providers and
loss to follow-up by reporting clinicians. Serial data were also
not routinely collected so we were unable to describe the pro-
portion of HCV infected children who subsequently cleared
their infection. However Australian data suggests that the
natural history of paediatric disease involves a long asympto-
matic period, and that treatment should be considered early
especially in children co-infected with HIV.19,38
No child in this study was receiving therapy at the time of
notification. Treatment options for HCV infection in children
were limited during the surveillance period.13 However, since
that time curative therapy has emerged and therefore timely
identification of childhood HCV is an imperative. Child health
providers should therefore promptly refer infants and children
with newly diagnosed HCV infection to a paediatric specialist
with expertise in childhood HCV infection (usually a paediatric
hepatologist). Specialist evaluation will include determination
of HCV genotype and viral load, consideration of antiviral
therapy and long term follow up for complications of HCV (liver
disease, hepatocellular carcinoma), and advice regarding other
hepatoprotective strategies (e.g. Hepatitis A vaccination). The
decision to commence antiviral depends on many factors
including the child’s age (most wait til three years of age to
start), HCV genotype, progression of liver disease, comorbidities,
and social circumstances.
Strengths of the study include the quality and detail of data
collected from paediatricians across the nation using the APSU
mechanism, which has very high monthly reporting rates.23
Limitations of this study include the small sample size, which
we infer is mostly due to the lack of uniform guidelines for
antenatal HCV testing and coordinated services for follow-up
and investigations of exposed or high risk children. Lack of
complete information on families and poor follow-up are a
function of conducting research in people, including illicit drug
users, who have limited engagement with the health system.21
Improved coordination of HCV services between antenatal and
child health providers and increased awareness of new, poten-
tial curative therapies by families and carers of HCV exposed
infants and children could increase screening rates and follow
up of these children nationally.
To our knowledge this is the first national Australian study
since the introduction of blood and blood product screening to
estimate the incidence and document known risk factors for
HCV infection in children. It is important that clinicians oppor-
tunistically investigate HCV status in high risk infants and chil-
dren when they intersect with the health care system. Key
opportunities include antenatal and perinatal visits and other
early childhood visits for vaccination. Testing for HCV antibody
and liver function or HCV-RNA at 18 months of age or older will
identify infected children and informed consent for testing
should be sought.30 Given the frequent loss to follow-up of these
children due to family dysfunction, HCV-RNA testing in young
infants from three months of age is also appropriate for identi-
fying infection.22,30,39 HCV testing in younger infants is insensi-
tive (i.e. the test can yield false negative results). Although HCV
RNA testing is recognised as the best diagnostic test for HCV in
infants < 18 months of age, to date Medicare rebate is not
available for this indication. With the anticipated increase in
vertical transmission of HCV, improved education for primary
care and other antenatal care providers regarding screening of
infectious diseases in pregnancy is essential for improving
outcomes.40,41
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